Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF - Get Free Report)'s stock price dropped 0.5% during trading on Wednesday . The stock traded as low as $26.80 and last traded at $26.80. Approximately 760 shares changed hands during mid-day trading, an increase of 1,602% from the average daily volume of 45 shares. The stock had previously closed at $26.93.
Analyst Upgrades and Downgrades
Separately, BNP Paribas began coverage on Hikma Pharmaceuticals in a report on Tuesday, May 13th. They set an "outperform" rating on the stock.
View Our Latest Stock Analysis on HKMPF
Hikma Pharmaceuticals Price Performance
The company has a current ratio of 1.14, a quick ratio of 0.65 and a debt-to-equity ratio of 0.28. The firm's 50 day moving average price is $27.70 and its two-hundred day moving average price is $26.95.
Hikma Pharmaceuticals Company Profile
(
Get Free Report)
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.
Recommended Stories
Before you consider Hikma Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hikma Pharmaceuticals wasn't on the list.
While Hikma Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access